Works matching AU Aurisicchio, L.

Results: 9

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy.

Published in:

2025

By:

Pinto, E.;
Lione, L.;
Compagnone, M.;
Paccagnella, M.;
Salvatori, E.;
Greco, M.;
Frezza, V.;
Marra, E.;
Aurisicchio, L.;
Roscilli, G.;
Conforti, A.

Publication type:

Literature Review

Overexpression of HER‐2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma ‐ A marker of malignancy and possible therapeutic target.

Published in:

Veterinary & Comparative Oncology, 2018, v. 16, n. 2, p. 297, doi. 10.1111/vco.12345

By:

Millanta, F.;
Impellizeri, J.;
McSherry, L.;
Rocchigiani, G.;
Aurisicchio, L.;
Lubas, G.

Publication type:

Article

Electro-gene-transfer as a new tool for cancer immunotherapy in animals.

Published in:

Veterinary & Comparative Oncology, 2014, v. 12, n. 4, p. 310, doi. 10.1111/vco.12006

By:

Impellizeri, J. A.;
Ciliberto, G.;
Aurisicchio, L.

Publication type:

Article

Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells.

Published in:

Cell Death & Disease, 2013, v. 4, n. 12, p. 1, doi. 10.1038/cddis.2013.444

By:

Noto, A.;
Raffa, S.;
De Vitis, C.;
Roscilli, G.;
Malpicci, D.;
Coluccia, P.;
Di Napoli, A.;
Ricci, A.;
Giovagnoli, M. R.;
Aurisicchio, L.;
Torrisi, M. R.;
Ciliberto, G.;
Mancini, R.

Publication type:

Article

Intratumor RNA interference of cell cycle genes slows down tumor progression.

Published in:

Gene Therapy, 2011, v. 18, n. 7, p. 727, doi. 10.1038/gt.2011.27

By:

Dharmapuri, S;
Peruzzi, D;
Marra, E;
Palombo, F;
Bett, A J;
Bartz, S R;
Yong, M;
Ciliberto, G;
La Monica, N;
Buser, C A;
Toniatti, C;
Aurisicchio, L

Publication type:

Article

Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2s-M2 tetracycline transactivator and repressor system.

Published in:

Gene Therapy, 2002, v. 9, n. 21, p. 1415, doi. 10.1038/sj.gt.3301813

By:

Salucci, V;
Scarito, A;
Aurisicchio, L;
Lamartina, S;
Nicolaus, G;
Giampaoli, S;
Gonzalez-Paz, O;
Toniatti, C;
Bujard, H;
Hillen, W;
Ciliberto, G;
Palombo, F

Publication type:

Article

Regulated and prolonged expression of mIFNα in immunocompetent mice mediated by a helper-dependent adenovirus vector.

Published in:

Gene Therapy, 2001, v. 8, n. 24, p. 1817, doi. 10.1038/sj.gt.3301596

By:

Aurisicchio, L;
Bujard, H;
Hillen, W;
Cortese, R;
Ciliberto, G;
La Monica, N;
Palombo, F

Publication type:

Article

An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.

Published in:

Cancer Gene Therapy, 2009, v. 16, n. 5, p. 462, doi. 10.1038/cgt.2008.91

By:

Dharmapuri, S.;
Aurisicchio, L.;
Neuner, P.;
Verdirame, M.;
Ciliberto, G.;
La Monica, N.

Publication type:

Article

CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge.

Published in:

Cancer Gene Therapy, 2007, v. 14, n. 2, p. 201, doi. 10.1038/sj.cgt.7701004

By:

Elia, L.;
Aurisicchio, L.;
Facciabene, A.;
Giannetti, P.;
Ciliberto, G.;
La Monica, N.;
Palombo, F.

Publication type:

Article

Works matching AU Aurisicchio, L.

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy.

Overexpression of HER‐2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma ‐ A marker of malignancy and possible therapeutic target.

Electro-gene-transfer as a new tool for cancer immunotherapy in animals.

Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells.

Intratumor RNA interference of cell cycle genes slows down tumor progression.

Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2<sup>s</sup>-M2 tetracycline transactivator and repressor system.

Regulated and prolonged expression of mIFNα in immunocompetent mice mediated by a helper-dependent adenovirus vector.

An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.

CD4<sup>+</sup>CD25<sup>+</sup> regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge.